# Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)

> **NCT01405937** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 51 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** vaniprevir
- **BIOLOGICAL:** peg-IFN
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT01405937
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-29
- **Primary completion:** 2013-02-26
- **Final completion:** 2013-03-12
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2018-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01405937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01405937, "Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01405937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*